Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Prepaid Assets: 2022-2025

Historic Prepaid Assets for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $13.2 million.

  • Phathom Pharmaceuticals' Prepaid Assets fell 11.70% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.2 million, marking a year-over-year decrease of 11.70%. This contributed to the annual value of $20.9 million for FY2024, which is 58.15% up from last year.
  • Phathom Pharmaceuticals' Prepaid Assets amounted to $13.2 million in Q3 2025, which was down 9.53% from $14.6 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Prepaid Assets ranged from a high of $20.9 million in Q4 2024 and a low of $975,000 during Q3 2022.
  • In the last 3 years, Phathom Pharmaceuticals' Prepaid Assets had a median value of $13.2 million in 2023 and averaged $13.7 million.
  • In the last 5 years, Phathom Pharmaceuticals' Prepaid Assets skyrocketed by 1,226.97% in 2023 and then decreased by 11.70% in 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' Prepaid Assets (Quarterly) stood at $5.1 million in 2022, then surged by 157.34% to $13.2 million in 2023, then spiked by 58.15% to $20.9 million in 2024, then decreased by 11.70% to $13.2 million in 2025.
  • Its last three reported values are $13.2 million in Q3 2025, $14.6 million for Q2 2025, and $13.1 million during Q1 2025.